重组人源化抗HER2单克隆抗体（喜康生物）

Recombinant humanized HER2 targeted monoclonal antibody (JHL Biotech)

Report date: 2022/03/10 10:28:23

Base Information

Drug Name重组人源化抗HER2单克隆抗体（喜康生物）
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesEden Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesXikang (Wuhan) Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A